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ABSTRACT 
 
Human serum albumin binding of folic acid and its γ-hydroxamate/carboxylate derivatives 
was studied by ultrafiltration and spectrofluorimetry, and it was found that the ligands exhibit 
a moderate binding (KD ~2-50 M), and the folate--phenylalanine represents the highest 
conditional binding constant towards albumin. This feature may have importance in the serum 
transport processes of these ligands. Interaction of folic acid and its derivatives with Zn(II) 
was investigated in aqueous solution to obtain the composition and stabilities of the 
complexes by the means of pH-potentiometry, 1H NMR and electrospray ionization mass 
spectrometry, together with the characterization of the proton dissociation processes and the 
hydro-lipophilic properties of the ligands. The formation of mono-ligand complexes was 
demonstrated in all cases and the contribution of the glutamyl carboxylates to the coordination 
was excluded. Binding of folic acid and its γ-carboxylate derivatives to Zn(II) via the 
pteridine moiety is suggested, while the (O,O) coordination fashion of the folate-γ-
hydroxamate ligands has importance in their inhibitory activity against Zn(II)-containing 
matrix metalloproteinases. It was found that the enzyme inhibition of these folate-γ-
hydroxamate ligands is mainly tuned by other features, such as the lipophilic character rather 
than the Zn(II)-chelate stability.  
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1. Introduction 
 
 Folic acid (pteroyl-L-glutamic acid, see Scheme 1) as a vitamin (B9) is essential for a 
wide range of biochemical pathways such as nucleotide biosynthesis, therefore, is a key 
molecule for cell replication. During periods of rapid cell division in various inflammatory 
states, the majority of malignant cells exceeds the expression of the high affinity folate 
receptors (FRs), which can selectively facilitate the transport of reduced forms of folic acid 
via the receptor mediated endocytosis [1-3]. This property makes FR a promising tumor target 
to deliver folate-linked diagnostic or therapeutic agents [1-3]. E.g. several radiolabelled folic 
acid conjugates such as 111In- diethylenetriaminepentaacetic acid (DTPA)-folate or 67Ga-
desferrioxamine-folate were developed for imaging of malignant tissues [4-7]. 
Scheme 1 
 Antifolates (methotrexate (MTX), pemetrexed, etc.) are also used in the clinical 
practice of cancer chemotherapy. They can inhibit the enzymes thymidylate synthase and/or 
dihydrofolate reductase (DHFR) [8,9]. -Monohydroxamate derivatives of MTX were 
synthesized as potential dual target antitumor agents in our former work, and they show 
inhibitory effect against two independent enzymes involved in metastasizing tumors, DHFR 
and matrix metalloproteinases (MMPs) [10]. MMPs are zinc-dependent endopeptidases and 
are frequently overexpressed in tumor progression [11-14]. Hydroxamic acids are particularly 
potent inhibitors of MMPs due to their bidentate (O,O) coordination to the catalytic Zn(II) 
center of the enzymes [15,16]. The folic acid analogues of the -monohydroxamate-MTX 
conjugates also represent inhibitory activity against different MMPs (MMP-2, 7, 9, 14) at 
micromolar level [10]. It was pointed out that insertion of an amino acid spacer (Phe, Pro) 
between the folate and the hydroxamate moieties improved the inhibitory potency [10]. 
Moreover, these molecules can be also considered as the model compounds for the MTX-
hydroxamate derivatives. 
 The efficacy of the -monohydroxamate-folic acid MMP inhibitor molecules is most 
likely strongly dependent on their binding ability to the catalytic Zn(II), additionally the fitting 
to the specificity pocket of the enzyme is also an important issue. On the other hand, the 
action and bioavailability of a drug can be influenced by other pharmacokinetic parameters 
such as the potential for binding to human blood serum proteins. It is well known that folic 
acid and its derivatives following the absorption can appear quickly in the blood circulation. 
A larger dose of folates may escape metabolism by the liver and they are present in their 
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original form, but are extensively bound to serum proteins [17]. Among the possible binders 
the high affinity folate binding protein and 2-macroglobulin are minor species, while the 
human serum albumin (HSA) is the most abundant blood serum protein (cHSA = 630 M) [18-
21], thus HSA may have an important role in binding folate conjugates and controlling the 
concentration the free (available) drug concentration.  
 Studies on the HSA and Zn(II) binding abilities can provide considerable contribution 
to the interpretation of the biological activity of the MMP inhibitor folate-hydroxamate 
conjugates. Therefore, interactions of Zn(II) with folate--hydroxamic acid (Fha), folate--
proline hydroxamic acid (FProha) and folate--phenylalanine hydroxamic acid (FPheha), 
shown in Scheme 1, were studied by different methods in this work. HSA binding strength 
and sites were also investigated in aqueous solution at physiological pH. Folic acid and the 
corresponding folate--carboxylic acids (see Scheme 1) were involved for comparison. 
Moreover, studies on complexation between folic acid and Zn(II) may help to understand the 
effect of folic acid on Zn(II) homeostasis [22] and only few information is available in the 
literature about the speciation of Zn(II)-folic acid complexes [23-26]. 
 
2. Experimental 
2.1. Chemicals 
 
 Fha, FProha, folate--proline (FPro), FPheha, folate--phenylalanine (FPhe) were 
prepared as it was described in our previous paper [10]. Folic acid, acetohydroxamic acid 
(Aha), benzoylglutamic acid (BzGlu), pterine (Pte), racemic warfarin, human serum albumin 
(with fatty acids) and apotransferrin (apoTf) were obtained from Sigma-Aldrich. The purity 
and stability of the folate derivatives, Pte, BzGlu and Aha were checked and the exact 
concentration of the stock solutions prepared was determined by the Gran method [27]. ZnCl2 
stock solution was made by the dissolution of anhydrous ZnCl2 in a known amount of HCl. 
The Zn(II) concentration was determined by complexometry via the EDTA complex and the 
accurate HCl concentration in the stock solution was obtained by pH-metric titrations. The 
concentrations of the protein solutions were estimated from their UV absorption: e280nm(HSA) 
= 36850 M−1cm−1 and e280nm(apoTf) = 92300 M
−1cm−1 [28,29]. 2-(N-
morpholino)ethanesulfonic acid (MES), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), Tris, N-cyclohexyl-2-aminoethanesulfonic acid (CHES) buffers and n-octanol were 
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obtained from Sigma-Aldrich. DMSO was freshly distilled before the preparation of the 
solutions, which were kept in dark. 
 
2.2. pH-Potentiometric studies 
 
The measurements for determining the protonation constants of the ligands and stability 
constants of the metal complexes were carried out at an ionic strength of 0.10 M (KCl) and at 
25.0±0.1 oC in DMSO:water 60:40 (w/w) mixed solvent as it was found to be sufficient for 
dissolution of the folate ligands at the concentration level necessary for the pH-metry (i.e. ≥1-
2 mM). The titrations were performed with a carbonate-free KOH solution of known 
concentrations (0.10 M). Concentrations of HCl and KOH were determined by pH-
potentiometric titrations. An Orion 710A pH meter equipped with Metrohm combined 
electrode (type 6.0234.100) and Metrohm 665 Dosimat burette were used for the pH-metric 
measurements. The electrode system was calibrated according to Irving et al. [30] and the pH-
metric readings could therefore be converted into hydrogen ion concentration. The average 
water ionization constant, pKw, is 16.22 ± 0.05 under DMSO:water 60:40 (w/w) solvent 
mixture condition at 25 oC [26]. The pH-metric titrations were performed in the pH range of 
2.0-13.0. Initial volume of the samples was 5.0 mL. The ligand concentration was in the range 
1-2 mM and the metal-to-ligand ratios in the range 1:1-1:4 were used. Due to the low 
solubility of the ligands, they were added directly to the samples as solids instead of preparing 
stock solutions. Following the titration of the ligand by KOH, samples were acidified back 
and the metal stock solution was added. The accepted fitting of the titration curves always 
was less than 0.01 mL. Samples were kept in dark and deoxygenated by bubbling purified 
argon for ca. 10 min before the measurements and argon was also passed above the solutions 
during the titrations. 
Protonation constants of the ligands were also determined in aqueous solutions by 
titrations with an HCl solution of known concentration (0.10 M) at an ionic strength of 0.10 
M (KCl) and 25.0±0.1 oC. Under this condition pKw is 13.76 ± 0.01 and the pH range of 11.5-
2 was monitored.  
Protonation constants of the ligands were determined with the computer program 
SUPERQUAD [31]. PSEQUAD [32] was utilized to establish the stoichiometry of the 
complexes and to calculate the stability constants (logLH). The calculations were always 
performed from data obtained prior to precipitation. The hydrolytic stability of these ligands 
was checked by a second titration with KOH following the back acidification of the initially 
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titrated sample. Constants calculated from the two consecutive titrations were found to be 
equal within ±0.05 log unites indicating that no decomposition occurred.   
 
2.3. Spectrophotometric, spectrofluorimetric and 1H NMR measurements 
 
The Unicam Helios Alpha spectrophotometer was used to record the spectra in the 
region of 260-800 nm at 25 oC. Path length was 1 cm. UV-Vis spectrophotometric titrations 
were performed on the folate ligands in the pH range 2-13 and the concentration was 50 M 
at an ionic strength of 0.10 M (KCl) in 60% (w/w) DMSO/H2O. Protonation constants and the 
individual spectra of the species were calculated by the computer program PSEQUAD [32]. 
UV-visible spectrophotometric measurements on systems containing HSA at 10 M 
and HEPES at 5 mM were performed by titration with 1 mM folic acid solution in order to 
obtain the difference spectra at pH 7.40. The HSA to ligand ratios were varied from 1:0.25 to 
1:4. Control titration measurements were carried out under the same conditions with samples 
containing only the HEPES buffer without HSA. 
Fluorescence spectra were recorded in a Hitachi-F4500 fluorimeter using 10 nm/10 
nm slit width in 1 cm quartz cell at 25.0±0.1 oC. The binding constants were calculated with 
the computer program PSEQUAD [32] and by the modified Stern-Volmer linearization [33] 
for comparison (see SI for the sample preparation and calculations). 
1H NMR studies were carried out on a Brucker Ultrashield 500 Plus instrument. Folic 
acid or Fha were dissolved in a 60% (w/w) d6-DMSO/D2O (Sigma-Aldrich) mixture in 0.5 
mM concentration and the Zn(II) to ligand ratios were 0:1 and 1:2. Chemical shifts are 
reported in ppm () from tetramethylsilane as internal reference in d6-DMSO.  
 
2.4. Determination of the distribution coefficients 
 
The distribution coefficients (Do/w) of the folic acid and the folate derivatives were 
determined by the shake-flask method [34] in n-octanol/buffered aqueous solution at pH 5.30; 
6.00 (MES); 7.40 (HEPES) and 8.00 (Tris) at 25.0±0.2 oC. All ligands were dissolved at 40 
M in the n-octanol pre-saturated aqueous solution of the buffer (0.01 M) containing KCl in 
0.10 M. After shaking the aqueous solutions with n-octanol for 3 h, the mixtures were 
centrifuged at 4000 rpm for 15 min by a temperature controlled centrifuge (Sanyo). Two 
parallel experiments were performed for each sample. After the separation of the two phases, 
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pH values of the aqueous solution were controlled and confirmed to be equal within ±0.02 
units to those of the starting buffered solution. UV-visible spectra of the ligands in the 
aqueous phase were compared with those of the starting aqueous solutions in the range 260–
410 nm. Do/w was calculated as the mean of (Absoriginal / Absaqueous phase – 1) obtained at the 
region of lmax ±10 nm.      
 
2.5. Membrane ultrafiltration 
 
Samples were separated by ultrafiltration through 10 kDa membrane filters (Microcon 
YM-10 centrifugal filter unit, Millipore). All 0.50 mL samples contained 200 M HSA and 
the folate ligands in 0.10 M HEPES buffer at pH 7.40 at 25.0±0.1 oC incubated for 2 h. The 
ligand concentrations were varied from 50 M to 1.2 mM. After the separation by a 
temperature controlled centrifuge (Sanyo, 10000/s, 45-50 min), the low molecular mass 
(LMM) fractions were obtained. The filtrates were diluted to 5.00 mL and the concentrations 
of the non-bound ligand were determined by UV-Vis spectrophotometry. Mixtures of HSA 
and ligands at various ratios were used and the non-bound ligand fractions were separated by 
ultrafiltration from the HSA and HSA–ligand complexes in the high molecular mass fractions. 
The UV-Vis spectra of the LMM fractions were always compared with the reference spectra 
of the samples containing the ligand without protein in an analytical concentration equal to 
that in the ultraﬁltered samples. Stoichiometries and conditional binding constants (log*) 
were then calculated with the computer program PSEQUAD [32] (see SI). 
 
2.6. Electrospray ionization mass spectrometry (ESI-MS) measurements 
 
ESI-MS spectra were recorded on a Waters Q-TOF Premier (Micromass MS 
Technologies, Manchester, UK) operating in positive ion mode. Samples were introduced into 
the ESI source by the syringe pump of the instrument. N2 was used as nebulizer and cone gas, 
and the source temperature was set to 120 °C. The capillary voltage was set to 3.8 kV. Argon 
was employed as the collision gas and the collision energy was –25 eV. Samples contained 
the ligands in 0.20 mM concentration and ZnCl2-to-ligand ratio was 0:1 or 1:2 in a non-
buffered aqueous solution and pH 7.40 was set by addition of aqueous NH3 and HNO3. 
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3. Results 
 
3.1. Proton dissociation processes 
 
Determination of the proton dissociation constants of folic acid and its derivatives 
(shown in Scheme 1) has some difficulties in aqueous solutions by standard techniques such 
as pH-potentiometry due to their poor solubility in water, especially at the acidic pH range 
where the carboxylate groups are protonated. Furthermore, they can undergo oxidative 
photodegradation [35]. It was also found that folic acid has a tendency for self-association 
above 80 mM concentration [36]. Therefore, protonation could be followed by titrations with 
HCl till the appearance of precipitate (pH ~6) in aqueous solution and proton dissociation 
processes by titrations with KOH in a DMSO/H2O solvent mixture when a wider pH range 
(pH 2–14) could be monitored. Aha, the simplest monohydroxamic acid and two prominent 
segments of folic acid, Pte and BzGlu were used as model compounds (shown in Scheme 1) 
for interpretation the data obtained for the folate ligands. Representative pH-potentiometric 
titration curves for folic acid and Fha in 60% (w/w) DMSO/H2O are shown in Fig. 1 (for the 
model ligands see Fig. S1). Protonation constants determined by pH-potentiometry in the 
DMSO/H2O mixture and in pure water are summarized in Tables 1 and 2, respectively. Data 
show that one pK could be determined for Aha, Pte, two for BzGlu, while three constants 
were calculated for the folate derivatives in the solvent mixture and only one or two in pure 
water.   
Table 1 
Table 2 
Fig. 1 
UV-Vis spectra of the folate ligands were recorded at different pH values in 60% 
(w/w) DMSO/H2O, which revealed characteristic pH-dependent spectral changes in the 
wavelength range 260–435 nm. Similar behavior and spectra of the ligands were observed for 
all ligands studied, only the compounds containing phenyl moiety showed additional 
absorption in the wavelength range 260-280 nm. Decomposition of the ligands was not 
detected during the timescale of the measurements. It is noteworthy that the deprotonation of 
the hydroxamic and carboxylic acid functions was not accompanied by measurable spectral 
changes. Representative spectra for folic acid along with the calculated individual spectra for 
the ligand species (HL2– and L3–) are shown in Fig. 2 and for FProha in Fig. S2. The intense 
ligand bands at lmax = 264 nm and 352/372 nm are assigned to the pteroyl fragments, while 
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the middle band (lmax = 286 nm) belongs to the p-aminobenzoate moiety [37]. A 
bathochromic shift from lmax = 352 nm to 372 nm, an increase in the absorbance of this 
absorption maximum (see Fig. S3), and a decrease at lmax = 286 nm with development of a 
new shoulder band at lmax = 264 nm could be observed due to the deprotonation at the pteroyl 
moiety. Isosbestic points at 271, 298 and 352 nm demonstrate that two species are involved in 
the equilibrium. Therefore, proton dissociation constants as microconstants for pteroyl moiety 
of the folate ligands (see Table 1) could be calculated based on the deconvolution of recorded 
UV-Vis spectra.  
Fig. 2 
Additionally, proton dissociation processes of Fha and those of folic acid for 
comparison were monitored by 1H NMR titrations. It was found that chemical shifts () of 
CH=N protons of the pteroyl moiety and CH=C-NH protons of the p-aminobenzoate residue 
exhibit reasonable sensitivity to the protonation state of both ligands (see Figs. 3 and S4). 
Upon deprotonation between pD ~7 and ~9 a significant upfield shift was obtained for the 
CH=N (s) protons and a minor downfield shift was observed for the CH=C-NH (d) protons. A 
downfield shift of  of the CH (t) glutamate proton between pD ~10‒12 was also observed 
that in the case of Fha. 
Fig. 3 
 
3.2. Characterization of the hydro-lipophilic properties of folate derivatives 
 
The hydro-lipophilic character of the folate ligands was investigated via the 
determination of distribution coefficient (Do/w) between n-octanol and buffered aqueous 
solutions in the pH range of 5.3–9.0. Do/w values for Fha, FProha, FPheha, folic acid, FPro 
and FPhe are depicted in Fig. 4 (see data in Table S1). The generally low solubility of the 
ligands in aqueous phase hindered the determination of the partition coefficient (P) referring 
to their neutral forms (H3L
0); and predicted logP values are listed in Table S1.              
Fig. 4 
 
3.3. Interaction with human serum albumin 
 
As a well-known drug carrier, HSA is able to bind mainly negatively charged, 
aromatic carboxylic acids (or large heterocyclic compounds) and to transfer them to the target 
tissues. HSA can solubilize poorly soluble drugs in the circulatory system via its ligand-
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binding ability and it can also delay the metabolic clearance of therapeutic agents [38,39], that 
is why the interaction of the folates with HSA may have importance. At first, difference UV-
Vis spectra were recorded at various protein-to-ligand ratios at physiological pH for samples 
containing the HSA and the simplest folate compound (folic acid), in order to obtain 
preliminary information whether the ligand binds to the protein. Difference spectra are 
depicted in Fig. 5, and measurable concentration-dependent DAbsorbance values were 
obtained due to the changes in the electronic structure of the ligand or the protein or both.  
Fig. 5 
Ultrafiltration–UV-Vis spectrophotometric measurements were carried out to 
determine the maximum number of ligands binding to HSA and the strength of the interaction 
in the case of folic acid, Fha, FPhe and Fheha. (Some typical UV-Vis spectra for the HSA–
FPheha system are illustrated in Fig. S5.) Ratio of the spectrum of the LMM fraction to that of 
the reference sample gives the proportion of the number of moles of non-bound ligand to the 
total number of moles of the ligand. From these data pairs, the stoichiometries and conditional 
stability constants were calculated (see SI); and the results are listed in Table 3. The measured 
equilibrium concentrations of the bound ligands together with the values calculated by using 
the determined stability constants are presented in Fig. 6.  
Fig. 6 
Table 3   
In addition, ultrafiltration –UV-Vis spectrophotometric measurements revealed that 
apoTf does not influence the binding of folic acid to HSA when blood serum conditions were 
used (see Fig. S6) according to the expectations based on literature data [20,21]. 
Fluorescence measurements were also performed on the binding properties of folic 
acid and its -hydroxamic and -carboxylic acid derivatives (Fha, FPhe, FPheha) towards 
HSA. This protein represents significant fluorescence as shown in the 3D spectra in Fig. 7.a 
due to the presence of the Phe, Tyr and Trp amino acids in its primary structure. It is well 
known that HSA contains a single Trp (at position 214) located in subdomain IIA, which can 
be selectively excited at lEX = 295 nm. The drug binding site I of HSA is situated nearby this 
Trp and ligand binding results in changes in its environment, which can be detected by 
spectrofluorimetry [39]. The fluorescence quenching of Trp-214 is clearly shown in the 
presence of folic acid in Figs. 7b, S7. Therefore, changes in fluorescence emission intensity of 
HSA were measured in the wavelength range 310–400 nm by the addition of the ligands at 
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various concentrations at lEX = 295 nm (see Fig.S8), and conditional binding constants 
(together with KD values) were calculated and are listed in Table 3.  
Fig. 7 
Constants only for the first ligand binding step could be obtained due to the strong 
dissociation in the highly diluted solutions (M range), which are ca. half order of magnitude 
higher than those obtained by the ultrafiltration–UV-Vis technique in a much higher 
concentration range. FPheha and Phe ligands have significant intrinsic emission at the 
excitation wavelength (see Fig. S9), which had to be considered in the calculations. Graphical 
solutions such as Stern-Volmer, Scatchard plots which are widely used in the literature 
[33,40], therefore, could not be not applied in the whole emission wavelength range, only 
where there is no ligand emission (e.g. lEM = 320 nm; see Fig. S8). Constants calculated by 
the modified Stern-Volmer linearization at lEM = 320 nm are also listed in Table 3 for 
comparison.  
Displacement reactions with the anticoagulant drug warfarin, which is the mostly used 
and known site marker fluorescence probe for the binding site I of HSA [41], were performed. 
First of all interaction between HSA and warfarin was studied under the conditions (for the 
calculation see SI and Fig. S10), and logK* = 5.81(1) conditional binding constant was 
obtained, that is similar to published work [41]. The weak fluorescence emission of warfarin 
increased when it binds to HSA, while the displacement of the bound warfarin by the folate 
ligands is accompanied by a decrease of the intensity. (Ligands have no intrinsic emission in 
the wavelength range 330–400 nm at lEX = 310 nm.) Among the folate ligands only FPhe 
could compete significantly with warfarin (see Fig. S11) 
 
3.4. Complex formation of folate derivatives with Zn(II) 
 
 The stability constants and stoichiometries of the complexes obtained upon pH-
potentiometric titrations of Zn(II) with folic acid and its -hydroxamic and -carboxylic acid 
derivatives in the 60% (w/w) DMSO/H2O solvent mixture are listed in Table 4. Calculations 
indicated the formation of mono-ligand species such as [ZnL]‒, [ZnLH-1]
2‒ and [ZnLH-2]
3‒ 
under the experimental conditions, and additionally [ZnLH] protonated complexes in the case 
of the hydroxamate derivatives. Stability constants for bis-ligand complexes could not be 
determined with certainty, therefore they were excluded from the accepted models. However, 
Roos et al. suggested the formation of bis-ligand complexes of folic acid [24]. Formation 
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constants for the complex [ZnL]‒ of folic acid obtained in aqueous solution by Kucharska et 
al. using different methods are somewhat lower than the our data [23,25].  
 In order to confirm the existence of these mono-ligand complexes ESI-MS was 
applied as data show in Table S2. The major signals in the ESI-MS spectra of the Zn(II)-folate 
systems arise from the metal-free ligands and the complexes with metal-to-ligand ratio 1:1. 
(The original number of the protons of the species in solution cannot be evaluated due to the 
limitation of this method.) Dimeric metal species or bis-ligand complexes could not be found 
by ESI-MS, while minimal dimerization of the metal-free ligands could be also observed 
owing to the stacking interactions e.g. between the pterine and the p-aminobenzoate rings 
[36]. 
Table 4 
 In order to obtain insight into the most probable binding modes of the folate 
derivatives, studies on complex formation of the model ligands, Pte, BzGlu and Aha with 
Zn(II) were also performed and the stability constants were determined (see Table 5). 
Negligible proton displacement from the ligand due to the Zn(II) coordination was observed 
during the titrations of Zn(II) and BzGlu containing systems, and the formation of a mixed 
hydroxide [ZnL(OH)2]
2‒ complex could be determined in the basic pH range, however, the 
coordination of the completely deprotonated ligand (L2‒) has no pH effect, hence its existence 
is rather uncertain. Pte was found to be a more efficient Zn(II) binder than BzGlu, and a 
similar stability data set was obtained as in the case of the -carboxylic acid derivatives. 
Table 5 
 1H NMR and ESI-MS fragmentation measurements were performed in order to obtain 
more information about the coordination modes in the Zn(II)-folic acid complexes. In the 1H 
NMR spectra of Zn(II)-folic acid system (see Fig. S12.a) the signals of the metal-free and 
complexed ligand could not be distinguished due to the fast proton- and ligand-exchange 
processes, but some differences could be detected in the presence of Zn(II) compared to the 
spectra of the ligand alone. The coordination of Zn(II) results in alteration in the  values of 
the CH=N and CH=C-NH protons monitored in the pH range of the formation of the mono-
ligand [ZnL]‒ complex in comparison with the signals of the metal-free ligands. 
ESI-MS collision-induced fragmentation (MS/MS) of the mono-ligand Zn(II) complex 
of folic acid (precursor ion: [M+Zn-H]+ at 504 m/z; see Figs. 8 and S13 for some ionization 
patterns) results in the appearance of the signals of the typical fragments of the metal-free 
folic acid [42,43] formed by the neutral loss of the p-aminobenzamido-glumatyl and the 
glutamyl residues together with the most abundant product p-aminobenzoyl cation. 
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Additionally, Zn(II) containing species could be also identified at 375, 331, 357 m/z obtained 
by the loss of the glutamyl and the glutamine monoamide moieties.       
Fig. 8  
  
4. Discussion 
 
4.1. Proton dissociation constants 
 
In order to gain insight into the proton dissociation steps of the folate--carboxylic and 
hydroxamic acids with the help of their pK values (see Table 1) those of the model ligands 
were analyzed first. Based on literature data it can be said that the pK of Aha is related to the -
CONHOH → -CONHO– deprotonation process [44]. pK of Pte belongs undoubtedly to the 
pteroyl moiety and following the deprotonation the negative charge is mainly transferred to 
the enolic oxygen via the lactam-lactim tautomeric equilibrium [45] as Scheme 2 shows. 
BzGlu presents overlapping deprotonation of the two carboxylic acid moieties; but the proton 
dissociation starts most probably at the -COOH group, while the intermolecular hydrogen 
bridge between the -COOH and the neighboring amide oxygen results in the deprotonation 
of the -carboxylic acid moiety taking place at higher pH [46]. 
Scheme 2 
 The three pK of the folate--carboxylic acids show overlapping proton dissociation 
steps, but the order of -COOH, -COOH and Pte moiety is the most probable based on the 
findings related to the model compounds above and literature data [46,47]. The deprotonation 
steps are much better separated in the case of the folate-γ-hydroxamic acids and the 
dissociation sequence of the -COOH, the Pte and the hydroxamic acid moieties is the most 
likely.  
pK values obtained in the DMSO/H2O solvent mixture and in water show significant 
differences owing to the change in the medium permittivity (see Tables 1,2). Namely, the 
carboxylic and hydroxamic acid groups exhibit higher pK in the presence of DMSO, since the 
pK of anionic bases are increased as the dielectric permittivity of the solvent is decreased 
[48]. The pK of the pteroyl moiety, however, show merely a minor drift in the various media 
due to the strong hydrogen binding interaction between the enolate and the solvent molecules 
[47,49]. 
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Effects of the various substituents on the pK values are also worth mentioning. 
Namely, the presence of the Phe and Pro residues results in lower pK of the hydroxamic and 
carboxylic acid functions (cf. pK(H3L), pK(H2L) of FPhe, FPro and those of folic acid; or 
pK(H3L), pK(HL) of FPheha, FProha and those of Fha in Table 1). It was also reported for 
simpler hydroxamic acids in our former work that phenyl and alkyl substituents on the carbon 
can decrease the pK value [44]. Additionally, the pK of the -COOH groups in the case of the 
hydroxamate derivatives is significantly lower (~ 5) compared with that of the dicarboxylates 
(~ 6) most probably due to electron withdrawing effect of the hydroxamic acid moiety at the 
-position, as it was observed for glutamic acid and the corresponding hydroxamate 
(glutamyl--hydroxamic acid) [50,51]. At the same time, the pK of the pteroyl moiety, which 
is far away from the substituents, does not show any considerably alteration in the case of the 
different folate ligands. The pK(Pte-OH) microconstants of the folate ligands obtained by UV-
Vis titrations (see Table 1) were also found to be quite similar in all cases.  
 The 1H NMR titrations revealed the similar changes of  of CH=N (s) and CH=C-NH 
(d) protons, which are located quite close to the Pte ring, in the case of folic acid and Fha. 
This finding strongly support that the deprotonation of Fha also takes place at the pteroyl 
moiety in the range pD ~7 ‒ 9, while the glutamate protons are found to be sensitive to the 
deprotonation of the hydroxamate residue.  
 
4.2. Hydro-lipophilic properties 
 
 Based on the Do/w values of the folate ligands (see Fig. 4, Table S1) it can be 
concluded that (i) these compounds are strongly hydrophilic in the studied pH range (logDo/w 
always lower than –0.9); (ii) lipophilicity of the ligands is decreased (lower Do/w values) with 
increasing pH due to the deprotonation resulting in higher negative charges; (iii) compounds 
with Phe moieties represent higher lipophilicity, (iv) hydroxamate derivatization yields a 
somewhat increased lipophilic character due to the higher pK values.  
 
4.3. Interaction with human serum albumin 
 
Difference UV-Vis spectra (in Fig. 5) clearly show the interaction between HSA and 
the folic acid since the spectra of the ligand and the protein are not additive, while no 
appreciable interaction between folic acid and the other important serum protein, apoTf,  was 
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found. The ultrafiltration studies reveal the formation of species with HSA:ligand 
composition of 1:1, 1:2 and 1:3, however, only the first binding step of the ligands has 
importance under realistic serum conditions, when the HSA to folate ratio is much less than 1 
(see Table 3).  
  Significant quenching of emission of Trp-214 by the folate ligands could be detected.  
The conditional stability constants calculated by the modified Stern-Volmer approach at a 
chosen lEM, where the intrinsic emission of the ligands is negligible, or by the PSEQUAD 
program using the whole spectra (taking into account the emission of the ligands with Phe 
moiety) were found to be similar (see Table 3). Among the folate ligands FPhe could displace 
the site marker warfarin most efficiently. Concentration distribution curves for the HSA–
warfarin–ligand systems calculated at various ligand concentrations (shown in Fig. S14) 
support this finding. 
Constants obtained by the ultrafiltration and the fluorimetric studies show a moderate 
binding of the folate ligands to HSA. Fha and FPheha exhibit somewhat higher protein 
binding affinity compared with folic acid, while FPhe has prominent ability to bind to the 
HSA. The site I of HSA is suggested to be their primary binding site.  
 
4.4. Zn(II) complexes of the  folates and the model compounds 
  
 Concentration distribution curves were calculated based on the stability constants 
collected in Table 4, and are plotted as a function of pH in order to compare the pH range and 
the extent of the complex formation in the Zn(II)‒folic acid and –Fha systems (see Fig. 9). 
Analysis of these curves shows that the coordination process starts with Fha at somewhat 
lower pH, with the formation of [ZnLH] complex, as compared with folic acid and a higher 
molar fraction of [ZnL]‒ when L=Fha. [ZnLH-1]
2‒ and [ZnLH-2]
3‒ species predominate above 
pH ~9, which should be regarded as mixed hydroxido complexes [ZnL(OH)]2‒ and 
[ZnL(OH)2]
3‒ resulting from the deprotonation of coordinated water molecules. FPro and 
FPhe ligands demonstrate similar stability constants and behavior as folic acid, while 
concentration distribution curves calculated for the hydroxamate derivatives revealed that 
FProha is a slightly weaker binder of Zn(II) compared to Fha and FPheha (not shown here), 
most probably because of the more rigid character of the Pro moiety. 
Fig. 9 
  All compounds studied as multidentate ligands provide different coordination 
possibilities: besides binding via the pteridinic moieties the folate--carboxylic acids may 
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coordinate via the glutamate, and the folate--hydroxamic acids via the hydroxamate oxygens. 
Literature data on the binding modes of complexes formed between folic acid and divalent 
transition metal ions show that the ligand can coordinate via the pteridinic (O(4-OH),N(5)) or 
mainly via the (O(4-OH),N(5),N(10)) donor sets [24,52-54] as it is depicted in Scheme 3, but data 
are rather contradictory for coordination via glutamate carboxylates [55,56]. 
Scheme 3 
Since the interaction between BzGlu and Zn(II) was found to be almost negligible (See Table 
5), coordination of folic acid and its -carboxylate derivatives via the pteridinic moiety is the 
most probable, and the contribution of the glutamate carboxylates is insignificant. The derived 
constant of Pte for the stability of the metal chelate compared with the proton complex (see 
the last row in Table 5) is somewhat lower as in the case of folic acid. Most probably the 
formation of the fused chelate rings ((O(4-OH),N(5),N(10)) coordination) in the Zn(II)-folate--
carboxylate complexes results in higher stability compared with the bidentate (O,N) binding 
mode of Pte.  
 1H NMR studies on the Zn(II)-folic acid system could confirm the pH range of the 
formation of the mono-ligand Zn(II) species, which is expected based on the speciation model 
and the higher  values in the presence of Zn(II) compared with those of the metal-free ligand 
at the same pH values are assumed due to the formation of the fused chelate rings, (O(4-
OH),N(5),N(10)) binding. The ESI-MS collision-induced fragmentation in the same system 
showed that the Zn(II)-pteridinyl coordination mode is preserved during the experiment. 
 In the case of the folate-hydroxamate derivatives coordination to Zn(II) via the 
hydroxamate oxygen donor atoms is assumed (see Scheme 3) since their inhibitory activity 
against a series of MMPs [10] is based on their ability to bind to the Zn(II) centers via the 
bidentate (O,O) set in contrast with folic acid, which is not active at all [10]. On the other 
hand, the pH-dependent conditional stability constants of the [ZnL] complex of folic acid and 
the model hydroxamic acid, Aha are quite comparable at neutral pH as Fig. 10 represents, and 
the (O,O) coordination mode becomes more favorable than the (O(4-OH),N(5),N(10)) only at the 
basic pH range. Thus, the folic acid type coordination of the folate-hydroxamate conjugates at 
the physiological pH range cannot be excluded; and 1H NMR results showed quite similar 
changes of the  values of the protons on the pteridinic moiety (see S11.b) as it was detected 
for folic acid. This finding suggests that these ligands may coordinate not merely via 
hydroxamate oxygens but also through the other donor atoms of the molecules to form 
linkage isomers. 
 16 
Fig. 10 
 
4. Conclusions 
 
Interaction of folic acid and various MMP inhibitor -hydroxamic acid derivatives 
with HSA in aqueous solution and with Zn(II) in a DMSO/water mixture was studied in order 
to clarify the stoichiometry and stability of the species formed. Some model ligands such as 
the analogue folate--carboxylic acid derivatives and prominent segment molecules (Aha, 
BnGlu, Pte) were involved for comparison. The folate ligands show highly hydrophilic 
character at physiological pH range, and the introduction of the hydroxamate and Phe 
moieties results in an increase in the lipophilicity. Moderate binding of the compounds to 
HSA was found, and folate--Phe exhibits the highest binding constant. This behavior may 
have effect on the transport processes of these ligands in the serum, thus on the rate of the 
metabolic clearance.  
Coordination of folic acid via the pteridine moiety was found in the Zn(II)-mono-
ligand complexes and the tridentate (O(4-OH),N(5),N(10)) binding mode is suggested. The Zn(II) 
complexes of the different folate-hydroxamate derivatives represent similar binding strength 
and the formation of linkage isomers (coordination via the pteridine or the hydroxamate 
group) is possible; however the bidentate hydroxamate-type binding to the active Zn(II) 
center is the most probable when these ligands act as inhibitors of the MMPs. It is noteworthy 
that the prominent inhibitory activity of the ligand FPheha [10] seems to be more determined 
by the lipophilic character, resulting in stronger hydrophobic interactions with the enzymes, 
than by the stability of the Zn(II)-chelate.        
 
Supplementary data 
Mathematical background of the calculation of the binding constants, figures for some 
titration curves, pH-dependent UV-Vis, 1H NMR spectra and chemical shifts, fluorescence 
spectra, ESI-MS results and concentration distribution curves are shown. 
 
 
5. Abbreviations 
 
Aha  acetohydroxamic acid 
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apoTf  apotransferrin 
BzGlu  benzoylglutamic acid 
CHES   N-cyclohexyl-2-aminoethanesulfonic acid 
CT  charge transfer 
Do/w  distribution coefficient 
DTPA  diethylenetriaminepentaacetic acid 
e  molar absorptivity  
ESI-MS electrospray ionization mass spectrometry 
Fha  folate--hydroxamic acid  
FPhe  folate--phenylalanine 
FPheha folate--phenylalanine hydroxamic acid  
FPro  folate--proline  
FProha folate--proline hydroxamic acid 
HSA  human serum albumin  
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
lEM  fluorescence emission wavelength  
lEX  fluorescence excitation wavelength  
LMM  low molecular mass  
MES  2-(N-morpholino)ethanesulfonic acid  
MMPs  matrix metalloproteinases 
P  partition coefficient 
Pte  pterine 
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Figures/Scheme Legends 
 
Scheme 1 Folate ligands used in this study: Fha = folate--hydroxamic acid; Folic acid; 
FProha = folate--proline hydroxamic acid; FPro = folate--proline; FPheha = folate--
phenylalanine hydroxamic acid and FPhe = folate--phenylalanine; and formulae of the 
model ligands: Aha = acetohydroxamic acid; BzGlu = benzoylglutamic acid; Pte = pterine. 
 
Scheme 2 Lactam-lactim tautomers of the pteroyl moiety. 
 
Scheme 3 Proposed binding modes of the coordination of the pteridinic (a) and the 
hydroxamate (b) moieties. 
 
Fig. 1 Representative pH-potentiometric titration curves for folic acid and Fha {cligand = 2 
mM; t = 25 ˚C, I = 0.10 M (KCl) in 60% (w/w) DMSO/H2O}. Negative base equivalent 
values mean acid excess. 
 
Fig. 2 UV-Vis absorption spectra of folic acid recorded at different pH values {cligand = 54 
M; t = 25 ˚C, I = 0.10 M (KCl) in 60% (w/w) DMSO/H2O}. Inset shows the calculated 
individual absorbance spectra of HL2- and L3- species of folic acid. 
 
Fig. 3 pD-dependent chemical shifts (ppm) for CH=N (s) and CH=C-NH (d) protons of folic 
acid (●) and Fha (×) measured by 1H NMR titration {cligand = 2 mM; 60% (w/w) 
DMSO/D2O}. 
 
Fig. 4 Octanol/water distribution coefficient (Do/w) of folic acid and some folate derivatives 
measured at different pH {cligand = 40 M; t = 25 ˚C, I = 0.10 M (KCl)}. (Data with Do/w = 0 
have the meaning that the UV spectra of the starting and the separated aqueous solutions did 
not show measurable differences (DAbs <0.005 at lmax)). 
 
Fig. 5 UV-Vis absorption difference spectra of folic acid – HSA system in addition of folic 
acid recorded at pH = 7.40 (5 mM HEPES) {cHSA = 10 M; HSA to folic acid ratio = 1:x 
where x = 0.5 (a),  x = 1 (b), x = 2 (c), x = 4 (d), t = 25.0 ˚C}. DAbsorbance = Abs(HSA-folic 
acid)  – (Abs(HSA) – Abs(folic acid). 
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Fig. 6 Ratio of the equilibrium concentrations of the bound folate ligand to c(HSA) vs. 
c(ligand)/c(HSA) for folic acid (♦), FPhe (▲), Fha (x) and FPheha (○) at pH = 7.40 (0.10 M 
HEPES). Calculated values on the basis of the determined associative conditional binding 
constants are also presented (solid lines: folic acid (a), FPhe (b), Fha (c) or FPheha (d)). 
 
Fig. 7 3D fluorescence spectra of HSA (a) and HSA – folic acid (1:10) system (b) {cHSA = 7.5 
M; t = 25 ˚C; pH = 7.40 (0.4 mM HEPES); PTM = 700 V; Slits: 10/10 nm}. 
 
Fig. 8 ESI-MS collision-induced fragmentation spectrum (MS/MS) of the parent peak of 
[M+Zn-H]+ at m/z 504 recorded in Zn(II) – folic acid (cfolic acid = 0.20 mM; M : L = 1:1; pH = 
7.50) 
 
Fig. 9 Concentration distribution curves for Zn(II)-folic acid (solid lines) and Zn(II)-Fha 
(dashed lines) systems {cligand = 1 mM; metal-to-ligand ratio 1:2; t = 25.0˚C, I = 0.10 M (KCl) 
in 60% (w/w) DMSO/H2O}. 
 
Fig. 10 The pH dependence of conditional stability constants logK(ZnL)* calculated for 
[ZnL] mono complexes of Zn(II) formed with folic acid (■) and the model ligand Aha (□) as 
representatives for the (O,N,NH) pteridinic  and (O,O) hydroxamate coordination modes, 
respectively. (logK(ZnL)* = log((ZnL)/H); H = 1 + (HL)×[H
+]) 
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Table 1 
Protonation and dissociation constants (log(HiL); pKi) of the folate-γ-hydroxamic and 
dicarboxylic acid derivatives and some model compounds [60% (w/w) DMSO/water; t =  25C; 
I = 0.10 M (KCl)]a 
 log  (HL) log (H2L) log (H3L) pK(H3L) pK(H2L) pK(HL) pK(Pte-OH)
d 
Folic acidb 8.34(2) 14.66(3) 19.52(4) 4.86 6.32 8.34 8.21(1) 
FPro 8.38(4) 14.41(5) 18.98(7) 4.57 6.03 8.38 8.02(1) 
FPhe 8.20(4) 14.14(5) 18.69(8) 4.55 5.94 8.20 8.07(1) 
Fha 10.91(9) 18.73(9) 24.1(1) 5.4 7.82 10.91 7.98(2) 
FProha 10.54(8) 18.50(5) 23.5(1)c ~5c 7.96 10.54 7.92(1) 
FPheha 10.41(5) 18.28(7) 23.28(9) 5.00 7.87 10.41 7.85(1) 
        
Aha 11.03(1) – – – – 11.03e  – 
BzGlu 6.35(1) 11.20(2) – – 4.85 6.35 – 
Pte 8.95(2) – – – – 8.87f  – 
a Standard deviations (SD) in parenthesis 
b Literature data under similar conditions {62.1% (w/w) DMSO/H2O; t = 25C; I =0.15 M, 
(KCl)}: pK1 = 4.91; pK2 = 6.41; pK3 = 8.10 [46]. 
c Not well determined due to the low solubility at lower pH range. 
d Determined by UV-Vis spectrophotometric titrations at pH > 7.5. 
e pKa of the hydroxamic acid moiety. 
f pKa of the pteroyl moiety. 
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Table 2 
Protonation and dissociation constants (log(HiL); pKi) of the folate-γ-hydroxamic and 
dicarboxylic acid derivatives in aqueous solution [t =  25C; I = 0.10 M (KCl)]a 
 log  (HL) log (H2L) pK(H2L) pK(HL) 
Folic acid 8.04(2) 12.96(7) 4.92 8.04b 
FPro 7.98(3) – – 7.98 
FPhe 8.07(6) – – 8.07 
Fha 9.19(2) 16.73(4) 7.54 9.19 
FProha 9.06(2) 16.62(4) 7.56 9.06 
FPheha 9.12(1) 16.42(3) 7.30 9.12 
     
Aha       9.27c – – 9.27d 
a Standard deviations (SD) in parenthesis. 
b pK (PteOH) = 8.06(2) determined by UV-Vis titrations. 
c Data taken from Ref. [44], {I = 0.20 M (KCl)}. 
d pK of the hydroxamic acid moiety. 
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Table 3 
Conditional binding constants (log’) of the HSA – folate complexes 
determined by ultrafiltration and spectrofluorimetrya 
 Folic acid Fha FPhe FPheha 
ultrafiltration     
log*
 
 (HSA-L)
b 3.92(4) 4.31(5) 5.04(5) 4.4(1) 
log*2(HSA-L2)
 b 7.29(6) 7.7(1) 8.6(1) 8.3(1) 
log*3(HSA-L3)
b  ~11 12.0(1) 11.7(2) 
     
logK*1
b 3.92 4.31 5.04 4.4 
logK*2
b 3.37 3.4 3.6 3.9 
logK*3
b  3.3 3.4 3.4 
spectrofluorimetry     
logK*c 4.67(5) 4.7(1) 5.74(4) 5.04(3) 
KD 
c 21.4 M 17.8 M 1.8 M 9.1 M 
logK*S.V.
d 4.6(1) 4.5(1) 5.4(1) 5.0(1) 
KD
d 56 M 36 M 5 M 10 M 
a Standard deviations (SD) in parenthesis. 
b t = 25°C; 0.10 M HEPES; cHSA = 0.200 mM.  
c t = 25°C; 0.4 m M HEPES; cHSA = 0.8 M; KD = 1/K* {lEX = 295 nm; lEM = 310–
400 nm}. 
d Calculated by the modified Stern–Volmer linearization of I0/( I0–I) vs. 1/cligand [33]; 
KD = 1/K* (lEX = 295 nm; lEM = 320 nm). 
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Table 4 
Overall stability constants of Zn(II) complexes of folate-γ-hydroxamic and dicarboxylic acid 
derivatives [60% (w/w) DMSO/water; t =  25C; I = 0.10 M (KCl)]a 
 Folic acid FPro FPhe Fha FProha FPheha 
log ([ZnLH]) – – – 14.74(13) 14.03(15) 14.35(9) 
log ([ZnL ]‒) 3.92(8) 3.98(9) 4.01(12) 7.56(5) 6.98(4) 6.98(4) 
log ([ZnLH–1] 
2‒) ‒4.69(8) ‒3.78(5) ‒3.55(7) ‒1.67(7) ‒1.80(5) ‒1.58(5) 
log ([ZnLH–2] 
3‒) ‒14.54(9) ‒11.96(4) ‒12.36(9) ‒12.11(10) ‒13.49(9) ‒12.76(9) 
fitting parameter (mL) 2.91×10-3 1.37×10-3 3.71×10-3 4.15×10-3 2.75×10-3 2.11×10-3 
a Standard deviations (SD) in parenthesis. 
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Table 5 
Overall stability constants of Zn(II) complexes of model compounds (Aha, Pte and BnGlu) 
[60% (w/w) DMSO/water; t =  25C; I = 0.10 M (KCl)]a 
 Aha Pte BnGlu 
log (ZnL)b 6.13(2) 3.9(1) – 
log (ZnLH–1)
b ‒2.11(4) ‒3.54(4) – 
log (ZnLH–2)
b ‒13.40(2) ‒12.71(5) ‒13.45(4) 
log (ZnL2)
b 11.75(5) – – 
log (ZnL3)
b 15.30(5) – – 
fitting parameter (mL) 2.95×10-3 7.49×10-3 7.23×10-3 
logK(ZnL) – pKc ‒4.90 ‒5.05 – 
a Standard deviations (SD) in parenthesis. 
b Charges are omitted for simplicity. 
c For folic acid: logK(ZnL) ‒ pK3 = ‒4.42. 
 
 
 
